The Latest Breaking News from Meridian Bioscience

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga · Jul 29, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

 

Benzinga · Jul 8, 2022

Looking Into Meridian Bioscience's Return On Capital Employed

According to Benzinga Pro, during Q2, Meridian Bioscience (NASDAQ:VIVO) earned $28.75 million, a 87.43% increase from the preceding quarter. Meridian Bioscience also posted a total of $111.23 million in sales, a 25.91% increase since Q1.

Benzinga · Jun 1, 2022

Why Meridian Bioscience's Shares Are Rising Today?

Meridian Bioscience Inc (NASDAQ: VIVO) has posted 

Benzinga · Feb 4, 2022

Meridian Bioscience: Q1 Earnings Insights

  Meridian Bioscience (NASDAQ:VIVO) reported its Q1 earnings results on Friday, February 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · Feb 4, 2022

Earnings Preview: Meridian Bioscience

Meridian Bioscience (NASDAQ:VIVO) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Meridian Bioscience will likely report an Earnings Per Share (EPS) of $0.25.

Benzinga · Feb 3, 2022